A two-year international study highlights the potential benefits of vagus nerve stimulation (VNS) therapy for individuals living with Lennox–Gastaut syndrome (LGS), a rare and severe form of childhood epilepsy. The findings demonstrate that long-term VNS therapy can reduce seizure frequency, improve quality of life, and maintain a favorable safety profile in a population that is often resistant to standard antiseizure medications .
Understanding Lennox–Gastaut Syndrome
Lennox–Gastaut syndrome is a complex neurological condition that typically begins in early childhood and is characterized by:
- Multiple types of seizures
- Severe, treatment-resistant epilepsy
- Developmental delay or loss of developmental skills
- Significant cognitive impairment
Many children with LGS continue to experience frequent seizures despite trials of multiple antiseizure medications, making alternative therapeutic approaches critically important.
What Is Vagus Nerve Stimulation (VNS) Therapy?
Vagus nerve stimulation therapy is an adjunctive treatment that delivers mild electrical impulses to the vagus nerve through an implanted device. These signals modulate brain activity and can help reduce seizure frequency and severity in certain types of epilepsy.
VNS therapy has been used for years in epilepsy care, particularly in patients who do not respond adequately to medications alone.
About the Two-Year Study
This study presents a plain-language summary of data collected from patients with Lennox–Gastaut syndrome who received VNS therapy and were followed for up to two years after implantation. The research included patients enrolled in an international registry and focused on real-world outcomes over an extended treatment period .
Study Population
- 60 patients with Lennox–Gastaut syndrome
- Most were children with severe cognitive impairment
- All participants continued to experience seizures despite having tried at least two and up to 17 antiseizure medications
Key Findings: Seizure Reduction and Quality of Life
Over the two-year follow-up period, VNS therapy was associated with:
- Reduction in overall seizure frequency
- Decreases in seizure types that cause loss of muscle control or sudden falls
- Fewer seizures that could lead to injuries, emergency room visits, or hospitalizations
Reducing these high-risk seizures is especially important, as falls and related injuries significantly impact both patient safety and caregiver burden.
Scheduled Programming and Treatment Optimization
The study also highlighted the role of scheduled programming, a feature of the VNS system that allows clinicians to gradually increase electrical stimulation at preset intervals to reach an effective therapeutic dose.
Patients with LGS were more likely to use scheduled programming compared with patients with other epilepsy types in the larger CORE-VNS registry, which may have helped them reach the recommended target dose more quickly and achieve better seizure control .
Safety and Tolerability
Consistent with previous research, VNS therapy was found to be safe and well tolerated. Reported side effects were generally mild and included:
- Temporary voice changes
- Coughing
- Neck or throat discomfort or pain
No unexpected safety concerns were identified during the two-year study period.
Why This Study Matters
Lennox–Gastaut syndrome is a lifelong and difficult-to-treat condition. Long-term studies involving large numbers of patients are rare, making this 24-month analysis particularly valuable. The findings provide important real-world evidence to help clinicians and families make informed treatment decisions.
Key Takeaways
- VNS therapy reduced all seizure types in patients with LGS
- Seizure reductions were especially meaningful for seizures associated with falls and hospital visits
- Improvements in quality of life were observed
- Long-term VNS therapy showed a favorable safety profile
Conclusion
The results of this two-year study support the use of vagus nerve stimulation therapy as an effective and safe adjunctive treatment for individuals with Lennox–Gastaut syndrome. By reducing seizure frequency—particularly dangerous seizure types—and improving quality of life, VNS therapy represents an important option for patients with this severe form of epilepsy.
